Search
eliglustat (Cerdelga)
Indications:
- long-term treatment of adults with Gaucher disease type 1
Dosage:
- start 42 mg PO BID
- increase dose in 4 weeks
- usual dose 84 mg PO BID
Capsule
Adverse effects:
- fatigue
- headache
- nausea
- diarrhea
- back pain
- pain in extremities
- upper abdominal pain
Mechanism of action:
- slows production of fatty material spleen, liver, & bone marrow
- similar efficacy to enzyme replacement with imiglucerase [1]
General
metabolic agent (metabolic modifier)
aromatic compound
ether
amide
alcohol
pyrrolidine; tetrahydropyrrole
Database Correlations
PUBCHEM correlations
References
- FDA News Release. August 19. 2014.
FDA approves new drug to treat a form of Gaucher disease.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm410585.htm